Published in Mol Cell on November 01, 2002
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell (2010) 7.59
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev (2004) 7.51
Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev (2008) 4.52
Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet (2008) 4.02
Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev (2006) 3.72
The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev (2004) 3.59
Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol (2005) 3.14
Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol (2013) 3.11
The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol (2010) 2.33
p63 induces key target genes required for epidermal morphogenesis. Proc Natl Acad Sci U S A (2007) 2.31
Plzf regulates germline progenitor self-renewal by opposing mTORC1. Cell (2010) 2.29
Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J (2011) 2.17
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci (2010) 2.15
Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes Dev (2013) 1.88
Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest (2012) 1.85
Hypercholesterolemia is associated with hyperactive cardiac mTORC1 and mTORC2 signaling. Cell Cycle (2009) 1.77
mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev (2012) 1.74
Rtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysema. Nat Med (2010) 1.67
ATF4 is necessary and sufficient for ER stress-induced upregulation of REDD1 expression. Biochem Biophys Res Commun (2008) 1.63
Differential recognition of response elements determines target gene specificity for p53 and p63. Mol Cell Biol (2005) 1.63
DeltaNp73beta is active in transactivation and growth suppression. Mol Cell Biol (2004) 1.56
The in vivo gene expression signature of oxidative stress. Physiol Genomics (2008) 1.55
New p63 targets in keratinocytes identified by a genome-wide approach. EMBO J (2006) 1.50
Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis. Proc Natl Acad Sci U S A (2010) 1.46
Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity. J Biol Chem (2012) 1.45
REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase. EMBO Rep (2009) 1.44
Distinct mechanisms of inadequate erythropoiesis induced by tumor necrosis factor alpha or malarial pigment. PLoS One (2015) 1.42
RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J Neurosci (2008) 1.37
Elevated corticosterone associated with food deprivation upregulates expression in rat skeletal muscle of the mTORC1 repressor, REDD1. J Nutr (2009) 1.35
FOXO-regulated transcription restricts overgrowth of Tsc mutant organs. J Cell Biol (2008) 1.34
A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol (2008) 1.34
Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA. PLoS Genet (2010) 1.34
The complexes of mammalian target of rapamycin. Curr Protein Pept Sci (2010) 1.33
Role of lung maintenance program in the heterogeneity of lung destruction in emphysema. Proc Am Thorac Soc (2006) 1.31
Short-term calorie restriction in male mice feminizes gene expression and alters key regulators of conserved aging regulatory pathways. PLoS One (2009) 1.28
Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget (2011) 1.27
The Role of p53 in Metabolic Regulation. Genes Cancer (2011) 1.25
mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol (2012) 1.24
The transcription factor p53: not a repressor, solely an activator. Cell Cycle (2014) 1.23
The mTORC1 signaling repressors REDD1/2 are rapidly induced and activation of p70S6K1 by leucine is defective in skeletal muscle of an immobilized rat hindlimb. Am J Physiol Endocrinol Metab (2012) 1.20
A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest (2011) 1.19
Identification and functional characterization of two new transcriptional variants of the human p63 gene. Nucleic Acids Res (2009) 1.19
An autoregulatory loop directs the tissue-specific expression of p63 through a long-range evolutionarily conserved enhancer. Mol Cell Biol (2006) 1.13
Mechanisms of transcriptional repression of cell-cycle G2/M promoters by p63. Nucleic Acids Res (2006) 1.13
p63 regulates glutaminase 2 expression. Cell Cycle (2013) 1.12
The regulation of cellular metabolism by tumor suppressor p53. Cell Biosci (2013) 1.12
REDD1 enhances protein phosphatase 2A-mediated dephosphorylation of Akt to repress mTORC1 signaling. Sci Signal (2014) 1.12
MotifMap: integrative genome-wide maps of regulatory motif sites for model species. BMC Bioinformatics (2011) 1.10
A p53-type response element in the GDF15 promoter confers high specificity for p53 activation. Biochem Biophys Res Commun (2007) 1.09
Glucocorticoid elevation of dexamethasone-induced gene 2 (Dig2/RTP801/REDD1) protein mediates autophagy in lymphocytes. J Biol Chem (2011) 1.08
The p53 tumor suppressor protein regulates hematopoietic stem cell fate. J Cell Physiol (2011) 1.08
p63 regulates olfactory stem cell self-renewal and differentiation. Neuron (2011) 1.06
Arsenite induces a cell stress-response gene, RTP801, through reactive oxygen species and transcription factors Elk-1 and CCAAT/enhancer-binding protein. Biochem J (2005) 1.06
Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling. FASEB J (2010) 1.05
A REDD1/TXNIP pro-oxidant complex regulates ATG4B activity to control stress-induced autophagy and sustain exercise capacity. Nat Commun (2015) 1.04
Structural analysis and functional implications of the negative mTORC1 regulator REDD1. Biochemistry (2010) 1.04
The role of p53 in cell metabolism. Acta Pharmacol Sin (2010) 1.03
Timosaponin AIII is preferentially cytotoxic to tumor cells through inhibition of mTOR and induction of ER stress. PLoS One (2009) 1.01
mTORC1 and p53: clash of the gods? Cell Cycle (2013) 0.98
Regulation of REDD1 by insulin-like growth factor-I in skeletal muscle and myotubes. J Cell Biochem (2009) 0.97
REDD1 protects osteoblast cells from gamma radiation-induced premature senescence. PLoS One (2012) 0.97
The Regulation of Aging and Longevity: A New and Complex Role of p53. Genes Cancer (2011) 0.97
RTP801/REDD1 regulates the timing of cortical neurogenesis and neuron migration. J Neurosci (2011) 0.96
ΔNp63 targets cytoglobin to inhibit oxidative stress-induced apoptosis in keratinocytes and lung cancer. Oncogene (2015) 0.95
RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiation. Exp Hematol (2007) 0.95
Frontier of epilepsy research - mTOR signaling pathway. Exp Mol Med (2011) 0.95
Micro-RNA30c negatively regulates REDD1 expression in human hematopoietic and osteoblast cells after gamma-irradiation. PLoS One (2012) 0.95
Feedback control of p53 translation by REDD1 and mTORC1 limits the p53-dependent DNA damage response. Mol Cell Biol (2011) 0.94
A Myc-microRNA network promotes exit from quiescence by suppressing the interferon response and cell-cycle arrest genes. Nucleic Acids Res (2013) 0.94
Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy. EMBO J (2015) 0.94
mTORC1 dependent regulation of REDD1 protein stability. PLoS One (2013) 0.92
Insulin induces REDD1 expression through hypoxia-inducible factor 1 activation in adipocytes. J Biol Chem (2009) 0.92
PKR, the double stranded RNA-dependent protein kinase as a critical target in Alzheimer's disease. J Cell Mol Med (2009) 0.90
Extremotolerant tardigrade genome and improved radiotolerance of human cultured cells by tardigrade-unique protein. Nat Commun (2016) 0.90
Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye (Lond) (2012) 0.89
Altered nutrient response of mTORC1 as a result of changes in REDD1 expression: effect of obesity vs. REDD1 deficiency. J Appl Physiol (1985) (2014) 0.89
The stress-response gene redd1 regulates dorsoventral patterning by antagonizing Wnt/β-catenin activity in zebrafish. PLoS One (2012) 0.89
Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells. Curr Cancer Ther Rev (2006) 0.88
Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling. Endocrinology (2014) 0.87
Targeting mTOR network in colorectal cancer therapy. World J Gastroenterol (2014) 0.86
Smoking and emphysema: the stress connection. Nat Med (2010) 0.85
p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase. Mol Cancer Res (2010) 0.85
Global gene expression analysis in time series following N-acetyl L-cysteine induced epithelial differentiation of human normal and cancer cells in vitro. BMC Cancer (2005) 0.85
Metabolite and transcriptome analysis during fasting suggest a role for the p53-Ddit4 axis in major metabolic tissues. BMC Genomics (2013) 0.85
Effect of protein kinase C delta (PKC-δ) inhibition on the transcriptome of normal and systemic sclerosis human dermal fibroblasts in vitro. PLoS One (2011) 0.84
Quantitative Lys-ϵ-Gly-Gly (diGly) proteomics coupled with inducible RNAi reveals ubiquitin-mediated proteolysis of DNA damage-inducible transcript 4 (DDIT4) by the E3 ligase HUWE1. J Biol Chem (2014) 0.84
Stress responses affecting homeostasis of the alveolar capillary unit. Proc Am Thorac Soc (2011) 0.83
Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes. EMBO Mol Med (2012) 0.83
Regulated in development and DNA damage responses -1 (REDD1) protein contributes to insulin signaling pathway in adipocytes. PLoS One (2012) 0.83
REDD1 functions at the crossroads between the therapeutic and adverse effects of topical glucocorticoids. EMBO Mol Med (2014) 0.83
Silymarin Suppresses Cellular Inflammation By Inducing Reparative Stress Signaling. J Nat Prod (2015) 0.83
REDD1/DDIT4-independent mTORC1 inhibition and apoptosis by glucocorticoids in thymocytes. Mol Cancer Res (2014) 0.82
Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease. Cell Death Dis (2014) 0.82
Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer. J Biol Chem (2014) 0.82
REDD2 expression in rat skeletal muscle correlates with nutrient-induced activation of mTORC1: responses to aging, immobilization, and remobilization. Am J Physiol Endocrinol Metab (2014) 0.82
Induction of REDD1 gene expression in the liver in response to endoplasmic reticulum stress is mediated through a PERK, eIF2α phosphorylation, ATF4-dependent cascade. Biochem Biophys Res Commun (2012) 0.82
Iodine alters gene expression in the MCF7 breast cancer cell line: evidence for an anti-estrogen effect of iodine. Int J Med Sci (2008) 0.82
Alterations of p63 and p73 in human cancers. Subcell Biochem (2014) 0.81
Understanding PLZF: two transcriptional targets, REDD1 and smooth muscle α-actin, define new questions in growth control, senescence, self-renewal and tumor suppression. Cell Cycle (2011) 0.81
Disruption of REDD1 gene ameliorates sepsis-induced decrease in mTORC1 signaling but has divergent effects on proteolytic signaling in skeletal muscle. Am J Physiol Endocrinol Metab (2015) 0.81
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (2004) 11.58
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (2013) 10.87
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell (2004) 8.06
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A (2010) 7.77
A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell (2006) 6.96
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A (2005) 6.82
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71
Circulating tumor cells: approaches to isolation and characterization. J Cell Biol (2011) 6.54
p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell (2007) 6.50
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol (2007) 5.55
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23
Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell (2007) 5.19
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci U S A (2004) 5.15
A public genome-scale lentiviral expression library of human ORFs. Nat Methods (2011) 4.98
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med (2013) 4.74
A recurrent mutation in PALB2 in Finnish cancer families. Nature (2007) 4.64
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 4.56
Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol Cell (2006) 4.51
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res (2012) 4.34
Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell (2005) 4.14
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res (2006) 4.11
Systematic evaluation of variability in ChIP-chip experiments using predefined DNA targets. Genome Res (2008) 4.08
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet (2005) 4.00
An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science (2007) 4.00
p63 protects the female germ line during meiotic arrest. Nature (2006) 3.98
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell (2006) 3.78
Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science (2011) 3.77
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet (2002) 3.57
Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol (2005) 3.54
RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature (2012) 3.40
Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer (2010) 3.33
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27
YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol (2009) 3.26
Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol (2005) 3.14
Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell (2011) 3.00
Histone H3-K9 methyltransferase ESET is essential for early development. Mol Cell Biol (2004) 2.92
Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res (2007) 2.78
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov (2012) 2.76
Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. Cancer Res (2008) 2.63
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov (2013) 2.61
Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res (2006) 2.59
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther (2008) 2.58
An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature (2012) 2.35
Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res (2007) 2.30
"Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res (2006) 2.30
Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer (2005) 2.19
The threshold pattern of calcineurin-dependent gene expression is altered by loss of the endogenous inhibitor calcipressin. Nat Immunol (2003) 2.17
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
Cancer: drivers and passengers. Nature (2007) 2.11
TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell (2012) 2.08
Amplification-free digital gene expression profiling from minute cell quantities. Nat Methods (2010) 2.07
Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. J Biol Chem (2005) 2.04
Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev (2010) 2.03
Structure-based design of novel inhibitors of the MDM2-p53 interaction. J Med Chem (2012) 2.01
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res (2005) 1.97
DOCK4, a GTPase activator, is disrupted during tumorigenesis. Cell (2003) 1.94
Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res (2010) 1.90
Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol (2009) 1.87
p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. Cancer Cell (2004) 1.86
The C. elegans Polycomb gene SOP-2 encodes an RNA binding protein. Mol Cell (2004) 1.85
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol (2009) 1.84
Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis. Cancer Cell (2002) 1.80
p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A (2005) 1.80
Modeling oncogene addiction using RNA interference. Proc Natl Acad Sci U S A (2008) 1.79
Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. Cancer Cell (2003) 1.78
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res (2006) 1.75
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist (2007) 1.75
A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. Genes Dev (2009) 1.73
A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol (2002) 1.73
Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation (2008) 1.72
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell (2008) 1.72
Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation (2005) 1.69
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med (2013) 1.67
The Tre2 (USP6) oncogene is a hominoid-specific gene. Proc Natl Acad Sci U S A (2003) 1.62
Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res (2006) 1.59
Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci U S A (2011) 1.58
Chromatin immunoprecipitation for determining the association of proteins with specific genomic sequences in vivo. Curr Protoc Mol Biol (2005) 1.58
Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res (2009) 1.54